A5048068061- Chronic Lymphocytic Leukemia Research
- Receptor Mechanisms and Signaling
- Nicotinic Acetylcholine Receptors Study
- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Cholinesterase and Neurodegenerative Diseases
- Neuropeptides and Animal Physiology
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
Novo Nordisk (Denmark)
2023-2024
University of Copenhagen
2019
University of Utah
2019
Saniona (Denmark)
2019
Prescribing information instructs taking oral semaglutide (a glucagon-like peptide-1 analogue) in the fasting state, followed by a post-dose period of ≥ 30 min. This trial compared recommended dosing schedule with alternative schedules. was randomised, single-centre, multiple-dose, open-label, five-armed, parallel-group healthy subjects who received once-daily (3 mg for 5 days 7 days). Subjects (n = 156) were randomised to five schedules: 2-, 4-, or 6-h pre-dose fast 30-min (treatment arms:...
The glucagon-like peptide-1 (GLP-1) analogue semaglutide is approved as an oral formulation for the treatment of type 2 diabetes. This study aimed to confirm bioequivalence between a new, second-generation (2G) (1.5, 4 and 9 mg) initially first-generation (1G) (3, 7 14 mg). was randomised, multicentre, open-label, full replicate crossover 2G 1G formulations at steady-state (SS) in healthy participants (NCT05227196). Participants were recruited three groups. In each group, randomised one two...